These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15716329)

  • 41. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists.
    Bahlmann FH; de Groot K; Mueller O; Hertel B; Haller H; Fliser D
    Hypertension; 2005 Apr; 45(4):526-9. PubMed ID: 15767470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiotensin II receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice.
    Takada S; Kinugawa S; Hirabayashi K; Suga T; Yokota T; Takahashi M; Fukushima A; Homma T; Ono T; Sobirin MA; Masaki Y; Mizushima W; Kadoguchi T; Okita K; Tsutsui H
    J Appl Physiol (1985); 2013 Apr; 114(7):844-57. PubMed ID: 23329824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
    Menne J; Ritz E; Ruilope LM; Chatzikyrkou C; Viberti G; Haller H
    J Am Heart Assoc; 2014; 3(2):e000810. PubMed ID: 24772521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus.
    Cherney DZ; Zinman B; Kennedy CR; Moineddin R; Lai V; Yang S; Miller JA; Prokopec SD; Boutros PC; Scholey JW; Reich HN
    Kidney Int; 2013 Dec; 84(6):1246-53. PubMed ID: 23760288
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.
    Ferrario C
    Vasc Health Risk Manag; 2009; 5(1):301-14. PubMed ID: 19436655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.
    Lorenzen JM; Neunhöffer H; David S; Kielstein JT; Haller H; Fliser D
    Atherosclerosis; 2010 Mar; 209(1):184-8. PubMed ID: 19801149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.
    Shimoura H; Tanaka H; Matsumoto K; Mochizuki Y; Hatani Y; Hatazawa K; Matsuzoe H; Ooka J; Sano H; Sawa T; Motoji Y; Ryo-Koriyama K; Hirata KI
    Heart Vessels; 2017 May; 32(5):584-590. PubMed ID: 27722772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Renal resistance and long-term blood pressure in individuals genetically predisposed for essential hypertension: 10-year follow-up of the Danish Hypertension Prevention Project.
    Buus NH; Mulvany MJ; Eiskjær H; Christensen KL; Skov K
    J Hypertens; 2016 Jun; 34(6):1170-7. PubMed ID: 27054529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.
    Cal LA; Maso LD; Caielli P; Pagnin E; Fusaro M; Davis PA; Pessina AC
    Blood Press; 2011 Dec; 20(6):376-82. PubMed ID: 21504378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gender differences in the renal response to renin-angiotensin system blockade.
    Miller JA; Cherney DZ; Duncan JA; Lai V; Burns KD; Kennedy CR; Zimpelmann J; Gao W; Cattran DC; Scholey JW
    J Am Soc Nephrol; 2006 Sep; 17(9):2554-60. PubMed ID: 16914541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat.
    Chappell MC; Gallagher PE; Averill DB; Ferrario CM; Brosnihan KB
    Hypertension; 2003 Oct; 42(4):781-6. PubMed ID: 12874087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade.
    Spiering W; Kroon AA; Fuss-Lejeune MJ; de Leeuw PW
    J Hypertens; 2005 Apr; 23(4):753-8. PubMed ID: 15775779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Olmesartan, microalbuminuria, and type 2 diabetes.
    Farmakis D; Aessopos A
    N Engl J Med; 2011 Jun; 364(23):2261-2; author reply 2262-3. PubMed ID: 21651398
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of olmesartan therapy on the expression of lung adrenoceptors in rats with chronic heart failure.
    Li YF; Jiang ZL; Cao FF; Liu F
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):6-12. PubMed ID: 25487981
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Ritz E; Viberti GC; Ruilope LM; Rabelink AJ; Izzo JL; Katayama S; Ito S; Mimran A; Menne J; Rump LC; Januszewicz A; Haller H
    Diabetologia; 2010 Jan; 53(1):49-57. PubMed ID: 19876613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in 24 h ambulatory blood pressure and effects of angiotensin II receptor blockade during acute and prolonged high-altitude exposure: a randomized clinical trial.
    Parati G; Bilo G; Faini A; Bilo B; Revera M; Giuliano A; Lombardi C; Caldara G; Gregorini F; Styczkiewicz K; Zambon A; Piperno A; Modesti PA; Agostoni P; Mancia G
    Eur Heart J; 2014 Nov; 35(44):3113-22. PubMed ID: 25161182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of black soy peptide supplementation on blood pressure and oxidative stress: a randomized controlled trial.
    Kwak JH; Kim M; Lee E; Lee SH; Ahn CW; Lee JH
    Hypertens Res; 2013 Dec; 36(12):1060-6. PubMed ID: 23924691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. No effects of atorvastatin (10 mg/d or 80 mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study.
    Tsikas D; Pham VV; Suchy MT; van de Ree MA; Huisman MV; Frölich JC; Princen HM;
    Pharmacol Res; 2015 Apr; 94():1-8. PubMed ID: 25662039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronic kidney disease accelerates cognitive impairment in a mouse model of Alzheimer's disease, through angiotensin II.
    Nakagawa T; Hasegawa Y; Uekawa K; Kim-Mitsuyama S
    Exp Gerontol; 2017 Jan; 87(Pt A):108-112. PubMed ID: 27916702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Angiotensin II receptor blockade and skeletal muscle metabolism in overweight and obese adults with elevated blood pressure.
    Boutagy NE; Marinik EL; McMillan RP; Anderson AS; Frisard MI; Davy BM; Rivero JM; Davy KP; Hulver MW
    Ther Adv Cardiovasc Dis; 2015 Apr; 9(2):45-50. PubMed ID: 25561011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.